Education
About Us
Working with TipRanks
Follow Us
Beyond Medical Technologies Inc (TSE:DOCT)
:DOCT
Top Page
Beyond Medical Technologies Inc
(DOCT)
Select Model
Select Model
Rating:34Underperform
Price Target:―
The overall stock score for Beyond Medical Technologies Inc is significantly impacted by its critical financial health, characterized by zero revenue and negative profitability. While technical indicators show short-term positive momentum, the overbought conditions and poor valuation metrics suggest caution. Immediate strategic changes are necessary for financial recovery and sustainable growth.
Positive Factors
Innovative Product Line
Beyond Medical Technologies Inc's focus on innovative medical solutions positions it well in the growing healthcare technology sector, potentially driving future demand and partnerships.
Strategic Collaborations
Strategic collaborations can enhance product development and market reach, providing opportunities for revenue diversification and technological advancements.
Telemedicine Platform
The telemedicine platform aligns with industry trends towards digital healthcare, offering potential for scalable revenue growth and increased market penetration.
Negative Factors
Zero Revenue
The lack of revenue generation is a critical issue, indicating challenges in product adoption and market penetration, which could hinder long-term sustainability.
Negative Profit Margins
Persistent negative profit margins suggest inefficiencies and cost management issues, which could impede the company's ability to achieve profitability.
High Leverage Risks
High leverage and negative equity pose substantial financial risks, limiting the company's ability to invest in growth and potentially affecting its solvency.
Beyond Medical Technologies Inc (DOCT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$9.67M
Dividend YieldN/A
Average Volume (3M)29.78K
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue GrowthN/A
EPS Growth-55.56%
CountryCA
EmployeesN/A
SectorIndustrials
Sector Strength72
IndustryIndustrial - Pollution & Treatment Controls
Share Statistics
EPS (TTM)<0.01
Shares Outstanding32,793,960
10 Day Avg. Volume26,926
30 Day Avg. Volume29,782
Financial Highlights & Ratios
PEG Ratio20.13
Price to Book (P/B)-0.45
Price to Sales (P/S)0.00
P/FCF Ratio-2.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Beyond Medical Technologies Inc Business Overview & Revenue Model
Company DescriptionRepublic Technologies, Inc. engages in the manufacturing of personal protective equipment. It operates through the following segments: Corporate, PPE Sector, and Waste Treatment. The company was founded by Bharath Bhushan on November 29, 2006 and is headquartered in Vancouver, Canada.
How the Company Makes MoneyBeyond Medical Technologies Inc generates revenue through the sale of its proprietary medical devices and technology solutions to healthcare providers, hospitals, and clinics. The company also monetizes its telemedicine platforms through subscription models and partnerships with healthcare institutions. Additionally, Beyond Medical Technologies Inc engages in strategic collaborations with pharmaceutical companies and research institutions to co-develop and license new technologies, contributing to its revenue streams.
Beyond Medical Technologies Inc Financial Statement Overview
Summary
Beyond Medical Technologies Inc faces severe financial challenges with zero revenue, negative profit margins, and high leverage risks. The financial statements indicate a critical need for strategic restructuring or pivoting to achieve financial stability and operational viability.Income Statement
Beyond Medical Technologies Inc has consistently reported zero revenue in recent periods, which is a significant concern. The company shows a downward trend in profitability with negative EBIT and net income, indicating ongoing operational challenges. The lack of revenue growth and negative profit margins highlight severe difficulties in achieving sustainable operations.10
Very Negative
Balance Sheet
The balance sheet reveals high leverage, with a negative stockholders' equity indicating significant liabilities exceeding assets. The debt-to-equity ratio is incalculable due to negative equity, which is a critical risk factor. The equity ratio is also concerning, showing negative equity relative to assets, highlighting financial instability and potential solvency issues.20
Very Negative
Cash Flow
Cash flow analysis reveals negative operating and free cash flows, indicating that the company is not generating sufficient cash from its operations to sustain its activities. The operating cash flow to net income ratio is negative due to continuous losses, underscoring financial distress. The inflow from financing activities suggests reliance on external funding to maintain liquidity.15
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 943.42K | 208.66K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -250.00K | -73.24K |
| EBITDA | -1.46M | -365.88K | -37.96K | -773.00K | -1.34M | -6.35M |
| Net Income | -1.73M | -285.00 | -596.00K | -1.40M | -2.91M | -6.52M |
Balance Sheet | ||||||
| Total Assets | 7.14M | 13.80K | 95.64K | 608.18K | 1.95M | 1.84M |
| Cash, Cash Equivalents and Short-Term Investments | 7.06M | 13.22K | 64.14K | 536.75K | 1.43M | 624.21K |
| Total Debt | 1.27M | 60.00K | 30.00K | 0.00 | 85.09K | 165.01K |
| Total Liabilities | 5.26M | 634.46K | 430.35K | 346.94K | 413.28K | 361.85K |
| Stockholders Equity | 1.88M | -620.66K | -334.72K | 261.25K | 1.54M | 1.48M |
Cash Flow | ||||||
| Free Cash Flow | -470.33K | -109.77K | -527.04K | -894.01K | -1.47M | -2.07M |
| Operating Cash Flow | -470.33K | -109.77K | -527.04K | -894.01K | -1.40M | -1.83M |
| Investing Cash Flow | -2.97M | 0.00 | 0.00 | 0.00 | -467.99K | -260.27K |
| Financing Cash Flow | 5.53M | 30.00K | 30.00K | 0.00 | 2.67M | -65.96K |
Beyond Medical Technologies Inc Technical Analysis
Negative
0.26
Price Trends
0.38
Negative
0.48
Negative
0.43
Negative
Market Momentum
-0.02
Negative
35.23
Neutral
46.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOCT, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.38, and below the 200-day MA of 0.43, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 35.23 is Neutral, neither overbought nor oversold. The STOCH value of 46.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOCT.
Beyond Medical Technologies Inc Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
50 Neutral | C$3.25M | -34.38 | -1.36% | ― | ― | -144.44% | |
47 Neutral | C$4.93M | -2.21 | ― | ― | -68.14% | -209.09% | |
47 Neutral | C$5.08M | -1.19 | ― | ― | ― | ― | |
45 Neutral | C$475.25K | -1.47 | ― | ― | ― | 19.70% | |
43 Neutral | C$3.74M | -4.55 | ― | ― | 17.30% | -200.00% | |
34 Underperform | C$9.67M | -3.32 | -319.50% | ― | ― | -55.56% |
* Industrials Sector Average
TSE:DOCT
Beyond Medical Technologies Inc
0.26
0.22
550.00%
TSE:APL
Appulse
0.22
0.01
4.76%
TSE:ATMO
Atmofizer Technologies Inc. Class B
0.06
0.02
50.00%
TSE:WATR
Current Water Technologies Inc
0.02
0.00
0.00%
TSE:SAY
Sparta Capital
0.02
0.00
0.00%
TSE:RGEN
Delta Cleantech
0.04
0.01
33.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.